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ABSTRACT
Objective: The aim of this study was to investigate whether a new generic rosuvastatin is 
non-inferior to a proprietary one in terms of lipid-lowering efficacy. We also evaluated its 
non-lipid effects including adverse events.
Methods: One-hundred and fifty-eight patients with cardiovascular risks requiring 
pharmacological lipid-lowering therapy were screened. After a 4-week run-in period, 126 
individuals who met the lipid criteria for drug therapy were randomly assigned to receive 
the new generic or proprietary rosuvastatin 10 mg daily for 8 weeks. The primary outcome 
variables were low-density lipoprotein-cholesterol (LDL-C) reduction and LDL-C target 
achievement. Hematological and biochemical parameters and adverse events were assessed.
Results: After 8 weeks of drug treatment, the mean percentage change in LDL-C was not 
different between the groups (−45.5%±19.9% and −45.1%±19.0% for generic and proprietary 
rosuvastatin, respectively; p=0.38). The LDL-C target achievement rate was similar between 
the groups (75.0% and 77.1% for generic and proprietary rosuvastatin, respectively; p=0.79). 
The percentage change in the other lipid profiles was not significantly different. Although 
generic- and proprietary rosuvastatins modestly affected creatine kinase and blood pressure, 
respectively, the changes were all within normal ranges. Incidence of adverse events did not 
differ between the receivers of the 2 formulations.
Conclusion: The new generic rosuvastatin was non-inferior to the proprietary rosuvastatin 
in terms of lipid-lowering efficacy. The rosuvastatin formulations did not exhibit clinically 
significant non-lipid effects with good safety profiles. Our study provides comprehensive 
data regarding 2 rosuvastatin formulations in East Asian subjects.
Trial Registration: ClinicalTrials.gov Identifier: NCT03949374
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INTRODUCTION
In the field of cardiovascular preventive medicine, statins have become an indispensable 
component. For several reasons, including cost-effectiveness, generic medications frequently 
replace proprietary medications. However, studies investigating the efficacy and safety of 
this class of medication are not sufficient. It has been reported that substituting generic for 
proprietary statin did not lead to any changes in efficacy and adverse events.1 Nevertheless, 
even after the introduction of several generic statins, a comprehensive evaluation of these 
formulations has not been commonly performed.
Lately, statins are being widely used in Asian countries. Appropriate use of statins in East 
Asians is a medical issue because it has been reported that this population is more sensitive 
to statins than other ethnicities.2,3 A few studies have shown that the responsiveness to 
low-dose statin is higher than expected in East Asians. However, comprehensive data on 
the efficacy and safety of statins, especially generic statins, are limited in East Asians. We 
aimed to investigate whether a new generic rosuvastatin is non-inferior to a proprietary one 
in terms of low-density lipoprotein-cholesterol (LDL-C)-lowering efficacy. We hypothesized 
that there would be no difference in LDL-C lowering efficacy of the two formulations. In 
addition, we assessed the effects of both rosuvastatin formulations on other lipid profiles and 
hematological and biochemical parameters. Finally, safety outcomes were also evaluated.
MATERIALS AND METHODS
1. Study participants
All participants provided written informed consent. Men and women aged 19 to 80 years 
were initially screened from October 2015 to April 2018. Statin-naïve individuals or those 
who were taking statins but provided consent to discontinue the medications for 4 weeks 
were eligible for the study. The participants had a variety of cardiovascular risks and required 
pharmacological lipid-lowering therapy according to the 2015 Korean Guidelines for the 
Management of Dyslipidemia.4 After a 4-week run-in period, individuals who met the 
lipid criteria requiring pharmacotherapy were enrolled in the study. The exclusion criteria 
included history of acute coronary syndrome, cerebrovascular diseases, percutaneous 
coronary intervention, and coronary artery bypass graft in the past 3 months; uncontrolled 
hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg); 
uncontrolled diabetes mellitus (hemoglobin A1c ≥9%); thyroid dysfunction; serum creatinine 
or transaminase level ≥2× the upper limit of normal; history of myopathy or creatine kinase 
level >2× the upper limit of normal; drug or alcohol abuse; hypersensitivity against the test 
medication; and pregnant or breast-feeding women or women of childbearing potential who 
are not using contraceptives.
2. Study design
This was a 12-week (4 weeks of wash-out/lifestyle changes and 8 weeks of drug treatment), 
randomized, open-label, active-control study. The protocol was approved by the Institutional 
Review Board of Severance Hospital, Seoul, Korea (No. 4-2015-0730; ClinicalTrials.gov 
identifier: NCT03949374). At the screening visit, the participants were interviewed about 
their medical history, and they underwent a physical examination and laboratory assessment. 
Individuals who met the inclusion criteria after the run-in period were randomly assigned to 
receive one of the following 2 regimens: a new generic rosuvastatin 10 mg (Rovasro; Whan In 
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Pharm Co., Ltd., Seoul, Korea) or proprietary rosuvastatin 10 mg daily (Crestor; AstraZeneca 
Korea, Seoul, Korea). Thereafter, the participants were followed-up at the end of week 8 for 
efficacy and tolerability. During the study, medications affecting patients' blood pressure 
were not changed.
Fasting blood samples were collected at randomization and at the end of week 8 of drug 
treatment. The samples were analyzed within 4 h of collection by a local laboratory certified 
by the Korean Society of Laboratory Medicine. Tolerability assessments were performed 
based on reported adverse events, history taking, physical examination, and laboratory 
evaluations. Drug-related adverse events were defined as any adverse events assessed by 
the investigators as “possibly related” or “related” to the study medication. Serious adverse 
events included death or events that are life-threatening, resulting in hospitalization or 
prolonging it, disability or permanent damage, or birth defect.
3. Statistical analysis
Primary outcome variables were percentage change and target achievement rate in the level 
of LDL-C from baseline to week 8 of drug treatment. The LDL-C target was defined as <70 
mg/dL for the very high risk group, <100 mg/dL for the high risk group, <130 mg/dL for the 
moderate risk group, and <160 mg/dL for the low risk group.4 Secondary outcome variables 
included percentage change in the level of total cholesterol, triglyceride, high-density 
lipoprotein-cholesterol (HDL-C), apolipoprotein (Apo)-B, Apo-A1, and high-sensitivity 
C-reactive protein (hsCRP). In addition, changes in blood pressure, hematologic parameters 
such as white blood cell count, hemoglobin level, and platelet count, and biochemical 
parameters such as creatinine, aspartate aminotransferase, alanine aminotransferase, and 
creatine kinase levels were compared before and after treatment with each formulation. A 
minimum of 50 participants were required per group, assuming a power of 80% and margin 
of 9.0 to report non-inferiority of the new generic rosuvastatin. A difference of 9%±16% 
(mean±standard deviation) in LDL-C between the groups was defined as significant. In 
expectation of a 20% dropout rate, at least 63 individuals per group were needed for the 
study. Efficacy analysis was performed in the population that underwent a follow-up test 
for laboratory values (full analysis set). Tolerability analysis was conducted for all the 
participants who took either of the 2 formulations at least once (safety set).
Continuous data are reported as mean±standard deviation, whereas categorical data are 
presented as frequency and percentage. Group differences in categorical variables were 
examined using the chi-square test, and those in continuous variables were assessed using 
Student's t-test. Paired t-test was used to evaluate the differences before and after treatment 
in each group. Differences between the 2 groups were considered significant when the 




A total of 158 patients were screened and 126 of them were randomized. After the run-
in period, 32 patients who did not meet the inclusion criteria were excluded. Of the 126 
randomized patients, 121 were included in the full analysis set. Among the 5 dropped-out 
patients, 3 in the Rovasro group and 1 in the Crestor group did not undergo laboratory 
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tests, whereas one in the Crestor group did not take the test medication. The clinical 
characteristics of the participants included in the full analysis set are shown in Table 1. The 
mean age was 59 years; 56 (26%) of the patients were male; 15 (12%) had diabetes mellitus. 
The mean baseline LDL-C level was 156 mg/dL (Table 2). Thirty-six (30%) and 13 (11%) 
patients belonged to the very high- and high-risk groups, respectively. Clinical variables did 
not differ between the 2 groups.
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Table 1. Baseline characteristics of the study population (full analysis set)
Characteristics Total (n=121) Rovasro® (n=60) Crestor® (n=61) p
Male 56 (46.3) 26 (43.3) 30 (49.2) 0.52
Age 59.0±7.1 60.3±10.6 57.6±9.6 0.14
Hypertension 72 (59.5) 35 (58.3) 36 (59.0) >0.99
Diabetes mellitus 15 (12.4) 9 (15.0) 6 (9.8) 0.56
Smoking 21 (17.4) 8 (13.3) 13 (21.3) 0.25
Hypercholesterolemia 69 (57.0) 34 (56.7) 35 (57.4) 0.94
Risk status 0.67
Very high 36 (29.8) 17 (28.3) 19 (31.2)
High 13 (10.7) 8 (13.3) 5 (8.20)
Moderate 48 (39.7) 25 (41.7) 23 (37.7)
Low 24 (19.8) 10 (16.7) 14 (23.0)
BMI (kg/m2) 25.2±2.0 25.5±2.9 24.8±3.2 0.21
Data are presented as number (%) or mean±standard deviation.
BMI, body mass index.
Table 2. Changes in lipid profiles and hsCRP after treatment (full analysis set)




% change −45.5±19.9 −45.1±19.0 0.38
























% change 77.1±399.8 61.4±277.7 0.70
The p-value for the inter-group comparison using the 2-sample t-test or Wilcoxon's rank sum test.
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density 
lipoprotein-cholesterol; Apo-B, apolipoprotein B; Apo-A1, apolipoprotein A1; CRP, C-reactive protein.
2. Changes in the lipid and other clinical parameters
After 8 weeks of drug treatment, the mean percentage of change in LDL-C was not different 
between the 2 groups (−45.5%±19.9% and −45.1%±19.0% in the Rovasro and Crestor groups, 
respectively; p=0.38). The LDL-C target achievement rate was similar between the groups 
(75.0% and 77.1% in the Rovasro and Crestor groups, respectively; p=0.79). The percentage 
change in the level of total cholesterol, triglyceride, HDL-C, Apo-B, Apo-A1, and hsCRP 
was not significantly different between the groups (Table 2). The systolic and diastolic 
blood pressure did not change in the Rovasro group (from 127±12 to 126±16 mmHg, p=not 
significant), whereas those in the Crestor group decreased after drug treatment (from 129±15 
o 125±14 mmHg, p=0.02).
2. Safety outcomes including hematologic and biochemical parameters
Hemoglobin level (from 14.3±1.5 to 14.0±1.4 g/dL in the Rovasro group, p=0.006; from 
14.5±1.4 to 14.3±1.3 g/dL in the Crestor group, p=0.008, reference 13–17 g/dL) and platelet 
count slightly decreased in both groups (from 261±50 to 250±51 ×103/μL in the Rovasro 
group, p<0.001; from 257±51 to 245±58 ×103/μL in the Crestor group, p<0.001, reference 
150–400 ×103/μL). However, all the values were within the normal range. Although alanine 
aminotransferase levels did not change in the Rovasro group (from 25.1±15.8 to 26.9±16.1 
IU/L, p=not significant), they increased in the Crestor group (from 21.3±10.8 to 25.6±13.3 
IU/L, p=0.003, reference 5–46 IU/L). On the contrary, creatine kinase levels increased in the 
Rovasro group (from 106±60 to 152±234 IU/L, p=0.009), but did not change in the Crestor 
group (from 119±86 to 118±94 IU/L, p=0.90, reference 44–245 IU/L). However, no participant 
in any of the groups showed an increase in alanine aminotransferase or creatine kinase levels 
by more than 10-fold the upper limit of normal.
The number of adverse events was 18 and 12 in the Rovasro and Crestor groups, respectively. 
The number of patients who experienced any adverse events was not different between the 2 
groups (15 [23.8%] and 12 [19.3%] in the Rovasro and Crestor groups, respectively, p=0.55). The 
proportion of patients who had drug-related adverse events was 9.7%–14.3%, whereas that of 
patients who had serious adverse events was 1.6%–3.2%; both were similar in the 2 groups. One 
serious event in the Rovasro group was prostate cancer, whereas 2 serious events in the Crestor 
group were pyelonephritis and arthritis. The most common events developed during the study 
were associated with the musculoskeletal and nerve systems, and the head and neck region in 
the order of frequency. Incidences of the adverse events including muscular or neurological 
systems were not significantly different between the 2 groups (Table 3).
DISCUSSION
In this study, the generic rosuvastatin was non-inferior to the proprietary rosuvastatin in terms 
of LDL-C reduction and target achievement rate. The efficacy in terms of changes in other 
lipid values was similar for the 2 rosuvastatin formulations. Only a few non-lipid parameters 
showed differential changes after treatment with the 2 rosuvastatin formulations: the generic 
rosuvastatin modestly increased creatine kinase, whereas the proprietary one decreased blood 
pressure and elevated liver enzyme slightly. The safety profiles including the number of patients 
with adverse events were not different between the receivers of the 2 formulations.
LDL-C reduction by rosuvastatin 10 mg has been reported to be approximately 46% in a pooled 
analysis of data mostly from Western countries.5 In the present study, LDL-C reduction was 
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approximately 45% in both groups, which was highly similar to that of the above-mentioned 
data. In previous studies performed in Korean population, the values ranged from 42.9% to 
52.0%.6-10 The LDL-C target achievement rate in our study was 75.0%–77.1%. In previous studies 
in Korea, the target achievement rate was relatively variable and ranged from 67.5% to 94.0%.7-10 
The cardiovascular risk status and baseline LDL-C of study populations varied in the studies, 
and the differences in the target achievement rates might be associated with these factors. 
Although studies analyzing the effect of generic rosuvastatin have not been common, one 
report from West Asia has showed that the generic one was efficacious and safe.11
The generic rosuvastatin used in our study did not exhibit a significant effect on blood pressure, 
whereas the proprietary one reduced blood pressure although it was not large. The blood 
pressure-lowering effect of statins reported to date has not been consistent. Simvastatin or 
atorvastatin use was associated with lower blood pressure, whereas rosuvastatin use was not. 
However, these findings have limited power as the studies were not elaborately designed.12,13 
Likewise, a few studies have shown that rosuvastatin, alone or in combination with valsartan, 
modestly reduced blood pressure.14,15 In our study, the effect of the rosuvastatin formulations on 
serum creatinine level was not significant. Although several studies have been conducted in this 
regard, the effects of statins including rosuvastatin on renal function have not been consistent 
either. A study performed in Japan revealed that atorvastatin and fluvastatin increased serum 
creatinine level.16 Furthermore, rosuvastatin has been demonstrated to be associated with acute 
kidney injury in Chinese patients undergoing cardiac surgery.17 In contrast, a meta-analysis 
reported that rosuvastatin can inhibit contrast nephropathy.18 Taken together, high-quality 
evidence regarding the influence of statin on renal function is still insufficient.19
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Table 3. Adverse events (safety set)
Adverse events Rovasro® (n=63) Crestor® (n=62) p
No. of subjects (%) No. of events No. of subjects (%) No. of events
Any adverse events 15 (23.8) 18 12 (19.3) 12 0.70*
Drug-related adverse events 9 (14.3) 9 6 (9.7) 6 0.60*
Serious adverse events 1 (1.6) 1 2 (3.2) 2 0.62
Musculoskeletal 5 (7.9) 6 3 (4.8) 3 0.72
Myalgia 4 (6.4) 4 2 (3.2) 2
Neck pain 1 (1.6) 1 0 (0) 0
Arthralgia 0 (0) 0 1 (1.6) 1
Nervous system 3 (4.8) 3 4 (6.4) 4 0.72
Dizziness 2 (3.2) 2 2 (3.2) 2
Headache 1 (1.6) 1 2 (3.2) 2
Head and neck 1 (1.6) 1 3 (4.8) 3 0.36
Facial edema 0 (0) 0 1 (1.61) 1
Erythema of eyelid 1 (16) 1 1 (1.6) 1
Blurred vision 0 (0) 0 1 (1.6) 1
Chest 2 (3.2) 2 1 (1.6) 1 >0.99
Chest pain 1 (1.6) 1 0 (0) 0
Cough 0 (0) 0 1 (1.6) 1
Dyspnea 1 (1.6) 1 0 (0) 0
Gastrointestinal 1 (1.6) 1 0 (0) 0 >0.99
Constipation 1 (1.6) 1 0 (0) 0
Infection 1 (1.6) 1 1 (1.6) 1 >0.99
Nasopharyngitis 1 (1.6) 1 0 (0) 0
Pyelonephritis 0 (0) 0 1 (1.6) 1
Laboratory abnormalities 1 (1.6) 3 0 (0) 0 >0.99
Liver enzyme elevation 1 (1.6) 1 0 (0) 0
Creatine kinase elevation 1 (1.6) 1 0 (0) 0
Gamma-glutamyltransferase elevation 1 (1.6) 1 0 (0) 0
The p-values with asterisk are from χ2 test. Other p-values are from Fisher's exact test.
In previous studies performed in Koreans, the incidence of treatment-emergent adverse 
events with rosuvastatin ranged from 7.6% to 23.7%,6,8,9,14,20 whereas that of drug-related 
adverse events was from 1.7% to 5.6%.6,8,9 In addition, the incidence of drug-related serious 
adverse events has been very low and ranged from 0% to 1.5% in Korean studies.9,10,14 An 
increase in liver enzyme by > 3 times the upper limit of normal after rosuvastatin use was rare, 
with 0.5%–1.3%.6,7 Conversely, an increase in creatine kinase by >5 or 10 times the upper limit 
of normal was observed in nearly none or 2.6% of Korean study populations.6,8
Our study has a few potential limitations. First, the sample size of our study was not sufficient 
to assess and compare the non-lipid effect and safety of the 2 rosuvastatin formulations. 
However, the primary purpose of the study was to examine the non-inferiority of the generic 
rosuvastatin in terms of lipid-lowering effect and we achieved this aim. Second, although 
our study described and compared the effect of 2 rosuvastatin formulations in Koreans, it 
is not clear whether our findings in this population are different from or similar to those in 
other ethnicities. However, no study has assessed the complete effect of generic rosuvastatin, 
particularly in East Asians, and the present study provides specific data in this regard. Third, 
data regarding differences of antihypertensive medications between the 2 groups, blood 
pressure lowering in hypertensive patients, and changes in diastolic blood pressure were not 
available. Further data on these issues might have given more insight on test medication.
In conclusion, the new generic rosuvastatin was non-inferior to the proprietary rosuvastatin 
in terms of lipid-lowering efficacy. Both rosuvastatin formulations did not exhibit clinically 
significant non-lipid effects, but presented good safety profiles. These results provide 
comprehensive data regarding the effects of 2 rosuvastatin formulations in East Asian subjects.
REFERENCES
 1. Rahalkar AR, Ban MR, Hegele RA. Clinical equivalence of proprietary and generic atorvastatin in lipid 
clinic patients. Can J Cardiol 2013;29:418-422. 
PUBMED | CROSSREF
 2. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-414. 
PUBMED | CROSSREF
 3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/
AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: 
a report of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Circulation 2019;139:e1082-e1143. 
PUBMED | CROSSREF
 4. Committee for the Korean Guidelines for the Management of Dyslipidemia. 2015 Korean Guidelines for the 
Management of Dyslipidemia: executive summary (English translation). Korean Circ J 2016;46:275-306. 
PUBMED | CROSSREF
 5. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev 
2014;11:CD010254. 
PUBMED | CROSSREF
 6. Lee SH, Cho KI, Kim JY, Ahn YK, Rha SW, Kim YJ, et al. Non-lipid effects of rosuvastatin-fenofibrate 
combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis 2012;221:169-175. 
PUBMED | CROSSREF
 7. Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, et al. Effect of fixed-dose combinations of 
ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter 
Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther 2016;34:371-382. 
PUBMED | CROSSREF
 8. Yang YJ, Lee SH, Kim BS, Cho YK, Cho HJ, Cho KI, et al. Combination therapy of rosuvastatin and 
ezetimibe in patients with high cardiovascular risk. Clin Ther 2017;39:107-117. 
PUBMED | CROSSREF
289https://doi.org/10.12997/jla.2020.9.2.283





 9. Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A phase III, multicenter, randomized, 
double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy 
with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: 
I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. 
Clin Ther 2018;40:226-241.e4. 
PUBMED | CROSSREF
 10. Kim W, Yoon YE, Shin SH, Bae JW, Hong BK, Hong SJ, et al. Efficacy and safety of ezetimibe and 
rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary 
hypercholesterolemia. Clin Ther 2018;40:993-1013. 
PUBMED | CROSSREF
 11. Betto M, Fares J, Saliba N, Ballout H. Efficacy and safety of a generic rosuvastatin in a real-world setting: 
prospective, observational clinical study in Lebanese patients. Ann Saudi Med 2017;37:366-374. 
PUBMED | CROSSREF
 12. You T, Liu XG, Hou XD, Wang XK, Xie HH, Ding F, et al. Effect of statins on blood pressure: analysis on 
adverse events released by FDA. Clin Exp Hypertens 2017;39:325-329. 
PUBMED | CROSSREF
 13. Presta V, Figliuzzi I, Citoni B, Miceli F, Battistoni A, Musumeci MB, et al. Effects of different statin types 
and dosages on systolic/diastolic blood pressure: retrospective analysis of 24-hour ambulatory blood 
pressure database. J Clin Hypertens (Greenwich) 2018;20:967-975. 
PUBMED | CROSSREF
 14. Jang JY, Lee SH, Kim BS, Seo HS, Kim WS, Ahn Y, et al. Additive beneficial effects of valsartan combined 
with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circ J 
2015;45:225-233. 
PUBMED | CROSSREF
 15. Rhee MY, Ahn T, Chang K, Chae SC, Yang TH, Shim WJ, et al. The efficacy and safety of co-administration 
of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. BMC Pharmacol Toxicol 
2017;18:2. 
PUBMED | CROSSREF
 16. Ooba N, Sato T, Wakana A, Orii T, Kitamura M, Kokan A, et al. A prospective stratified case-cohort study 
on statins and multiple adverse events in Japan. PLoS One 2014;9:e96919. 
PUBMED | CROSSREF
 17. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, et al. Perioperative rosuvastatin in cardiac surgery. 
N Engl J Med 2016;374:1744-1753. 
PUBMED | CROSSREF
 18. Liang M, Yang S, Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing 
contrast-induced nephropathy: a meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 
2017;96:e7384. 
PUBMED | CROSSREF
 19. Lewicki M, Ng I, Schneider AG. HMG CoA reductase inhibitors (statins) for preventing acute kidney 
injury after surgical procedures requiring cardiac bypass. Cochrane Database Syst Rev 2015;11:CD010480. 
PUBMED | CROSSREF
 20. Park JS, Shin JH, Hong TJ, Seo HS, Shim WJ, Baek SH, et al. Efficacy and safety of fixed-dose combination 
therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate 
hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study 
(OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des Devel Ther 2016;10:2599-2609. 
PUBMED | CROSSREF
290https://doi.org/10.12997/jla.2020.9.2.283
Effects of New Generic Rosuvastatin
https://e-jla.org
Journal of 
Lipid and 
Atherosclerosis
